A bioprintable material is provided. The bioprintable material includes a hydrogel and microfilaments mixed in the hydrogel. The hydrogel includes a first collagen. The microfilament includes a second collagen. The diameter of the microfilament is ranging from 5 microns to 200 microns. The weight ratio of the microfilaments to the first collagen is ranging from 0.01:1 to 10:1.

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

Provided herein are methods of producing a recombinant protein that include fed-batch culturing a mammalian cell.

Cell culture media, concentrated media and feeds, methods of manufacturing cell culture media and feeds, and methods of culturing cells are provided. One or more small peptides, including dipeptides are added to the cell culture media to provide improved stability and improved conditions for culturing cells.

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.

An object of the present invention is to provide human fatty-liver model cells showing symptoms of the hepatic tissue of fatty liver. The present invention relates to human fatty-liver model cells, which are produced by culturing human hepatocytes derived from fatty liver in a medium containing dimethyl sulfoxide.

The invention is directed to Haematococcus sp. KAU-01 as well as to a culture medium for Haematococcus sp. KAU-01, and to methods for using this strain to process environmental pollutants such as gases generated by coal-fired plants.

The present invention provides a method for proliferating neural progenitor cells and a composition for treating neurological diseases, the composition including a proliferated neural progenitor cell. When a fetal neural progenitor cell is cultured under a hypoxia condition and/or in a medium containing tocoperol, tocoperol acetate, or a mixture thereof, the improved cell proliferation rates of the fetal neural progenitor cell are confirmed. In addition, considering an effect of the neural progenitor cell on preventing differentiation thereof into neurons at the time of proliferation, the present disclosure may contribute to mass production of neural stem cells, and accordingly, the proliferated neural progenitor cell is expected to be utilized in the treatment of a neurological disease.

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (i PS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.